Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent provided for the subject by a parent or legal guardian.~* Subjects whose parents the investigator believes can and will comply with the requirements of the protocol (i.e. return for follow-up visits, record safety observations, able to converse with study personnel including by telephone).~* Age 12-59 months at Visit 1, male or female~* Receipt of one or two doses of Arepanrix (adjuvanted H1N12009 vaccine, GlaxoSmithKline (GSK)) in 2009 documented by written record or attested by a confident personal recollection (window for vaccination will be 1 October 2009 to January 31, 2010).~Exclusion Criteria:~* Systemic hypersensitivity to hens' eggs or to any other Fluviral S/F vaccine component such as thimerosal~* History of a life-threatening reaction to any influenza vaccine~* Receipt of Arepanrix after January 31st , 2010~* Receipt of non-study TIV (Trivalent Influenza Vaccine)for the 2010-2011 season~* Receipt of any live vaccine within 4 weeks or inactivated vaccine within one week of study entry or planned administration of any non-study vaccines during the study period~* Thrombocytopenia or any bleeding disorder that contraindicates IM injection or blood collection~* Receipt of blood or any blood-derived products within the past 3 months~* Chronic illness at a stage that could interfere with trial participation (stable health conditions are acceptable, such as diabetes, lung disease, heart conditions etc)~* Immune compromise as a result of a medical condition, transplantation or immunosuppressive medication, not including topical or aerosol medications~* Participation in any other research study involving a non-approved drug or medical device

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 59 Months
- Healthy Volunteers: t

Study Arms:
- Fluviral (Type: EXPERIMENTAL): 0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age

Based on this trial design, predict the completion outcome and termination type (if applicable).